Beau Webber, PhD

Beau Webber, PhD, is associate professor in the Division of Pediatric Hematology/Oncology, co-director of the GESR, and a member of the Stem Cell Institute at the University of Minnesota Medical School, where he is also a faculty member in the Department of Pediatrics, the Molecular Pharmacology & Therapeutics Graduate Program, and the Masters Program in Stem Cell Biology. He is also a member of the Masonic Cancer Center.

Articles by Beau Webber, PhD

Branden Moriarity, PhD, associate professor, Division of Pediatric Hematology/Oncology, co-director, Center for Genome Engineering, Genome Engineering Shared Resource (GESR), member, Center for Genome Engineering, University of Minnesota, member, Stem Cell Institute, Masonic Cancer Center; Beau Webber, PhD, associate professor. Division of Pediatric Hematology/Oncology, co-director, GESR, member, Stem Cell Institute, University of Minnesota Medical School, member, Masonic Cancer Center.

CRISPR-Edited CISH Knockout TIL Therapy Paves Novel Treatment Paths in CRC: With Branden Moriarity, PhD; and Beau Webber, PhD

ByBranden Moriarity, PhD,Beau Webber, PhD

July 28th 2025

Drs Moriarity and Webber discuss a study evaluating neoantigen-reactive CISH knockout TIL therapy in patients with metastatic gastrointestinal cancers.

Beau Webber, PhD

Articles by Beau Webber, PhD

CRISPR-Edited CISH Knockout TIL Therapy Paves Novel Treatment Paths in CRC: With Branden Moriarity, PhD; and Beau Webber, PhD

Latest Updated Articles

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma

Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies